

Opt-out HIV and HCV testing among jail inmates

De La Flor C, MD^{1,2}, Porsa E, MD, MPH³, Nijhawan AE, MD, MPH, MSCS^{1,2},

¹University of Texas Southwestern Medical Center, Division of Infectious Diseases, Dallas, TX

²Parkland Health and Hospital Systems, Dallas, TX, ³Office of Strategy and Integration,

Parkland Health and Hospital Systems, Dallas, TX

Carolina De La Flor, MD carolina.delaflor@phhs.org

Poster number 957

BACKGROUND

- The burden of HIV is around four times higher and the HCV positivity rate is up to ten times higher in correctional facilities compared to the general population¹
- Incarceration provides a unique opportunity to perform HIV/HCV screening in high-risk and hard-to-reach individuals
- The CDC recommends routine opt-out HIV testing in jails and prisons, however only 19% of prisons and 35% of jails offer this service²
- The WHO recommends that all inmates should be tested for HCV, however only 12 to 15 states in the US report performing routine HCV screening.^{3,4} In the US, HCV screening is focused mainly on individuals born between 1945-1965 ("baby boomer" cohort)

OBJECTIVES

- ☐ To describe the results of an opt-out combined HIV and HCV testing program in a criminal justice system
- ☐ To determine the prevalence and demographic characteristics of HIV and HCV in this population

METHODS

- ☐ Opt-out HIV/HCV testing was offered to individuals entering the Dallas County


 Jail between October 2015 and July 2016 at the time of a scheduled blood

 draw
- ☐ HIV testing was performed using the 4th generation Ag/Ab test (LabCorp)

 Laboratories, Redmond, WA) and HCV antibody assay (BioRad) was used to screen for HCV
- ☐ Basic demographics were extracted from electronic health records
- ☐ For those who tested HIV positive, risk factors, prior engagement in care (seen by and HIV provider within 6 months previous to incarceration), and re-engagement in care (receipt of HIV care during incarceration) were assessed
- ☐ For those who tested HCV positive, prior seropositivity was determined by chart review
- □ SAS statistical software, v9.4 (SAS Enterprises, Inc. Cary, NC) was used for all analyses

HIV OPT-OUT TESTING

Figure 1. Flow diagram outlining the HIV screening process.



* Known diagnosis = previous documented HIV-positivity in jail records

HCV OPT-OUT TESTING

□ Mean age: 49
□ 80% men
□ One third (177/500) had previous documented HCV Ab positivity

☐ Positive HCV Ab: **16**% (500/3042)

☐ Only 52% (258/500) born in the "baby-boomer" cohort

Table 1. Baseline characteristics of the HIV-positive population

RESULTS

True positives=30

		True positives=30	
		New Diagnosis=6	Known Diagnosis ^a =24
Age (mean ± SD)		27 ± 10.4	38.9 ± 12
Gender	Male	6 (100%)	21 (87.5%)
	Female	0 (0%)	3 (12.5%)
Race	White	1 (16.7%)	4 (16.7%)
	Black	4 (66.7%)	17 (70.8%)
	Hispanic	1 (16.7%)	3 (12.5%)
Risk Factors ^b	IDU	0 (0%)	2 (18.3%)
	Heterosexual	4 (66.7%)	14 (58.3%)
	MSM	2 (33.3%)	13 (54.2%)
	Unknown	•	1 (4.2%)
	Yes	0 (0%)	6 (25%)
Undetectable VL ^c	No	6 (100%)	15 (62.5%)
ART ^d	Unknown	•	3 (12.5%)
	Yes	3 (50%)	18
	No	3 (50%)	5
	Unknown	•	1
HCV Ab positive	Yes	0 (0%)	6 (25%)
	No	6 (100%)	16 (66.7%)
	Unknown	•	2 (8.3%)
Inmate disclosed HIV status	Yes	•	21 (87.5%)
	No	•	1 (4.2%)
	Unknown	•	1 (4.2%)
Engagement in are ^e before in jail (6 month before)	Yes	•	14 (58.3%)
	No	•	6 (25%)
	Unknown	•	4 (16.7%)
Engagement in care while in jail	Yes	6 (100%)	18 (75%)
	No	0 (0%)	6 (25%)
	Unknown	•	•
Engagement in care post jail (6 months after)	Yes	6 (100%)	8 (33.3%)
	No	0 (0%)	13 (54.2%)
	Unknown	•	9(37.5%) ^f
a Known diagnosis = pre	evious documente	ed HIV-positivity in igil record	ds.

- ^a Known diagnosis = previous documented HIV-positivity in jail records
- c Undetectable VL = viral load < 200 copies/mL
- d ART = antiretroviral therapy was initiated, continued or re-started while in jail
- ^e Engagement in care = any clinic visit with a medical provider in a 6 month period ^f 8 patients were scheduled to follow up with clinics outside our system
- Abbreviations: $IDU = injection drug users^r MSM = men who have sex with men,$

Figure 2. HCV Ab positivity by race





Figure 3. HCV Ab positivity by birth cohort and race



CONCLUSIONS

- ☐ Routine opt-out testing in a jail setting identified multiple HIV and HCV infections
- □ New HIV diagnoses were relatively rare 6/3155, though above CDC recommended thresholds for testing (1.0% prevalence, 0.12 incidence); linkage to HIV care and re-engagement in care were high
- ☐ The rate of HCV Ab positivity was high and one-third was already aware of this diagnosis
- ☐ Testing only those in the baby boomer cohort would have missed approximately half of HCV infections, predominately among whites
- □ HCV Ab positivity was > 2X higher in Whites vs Blacks among those born after 1965, and nearly 2X higher among in Black vs White baby-boomers (born 1945-1965)

LESSONS LEARNED/ BEST PRACTICES

- ☐ Opt-out HIV and HCV testing is feasible in the correctional health setting
- Existing linkage to HIV care programs within the jail are robust, however, consider additional resources for this after release
- ☐ HCV testing should be offered to all inmates, regardless of whether they are baby boomers or not
- ☐ Need to add reflex HCV RNA testing to confirm HCV infection and increase HCV education and linkage to care programs

REFERENCES

- 1. Goug E, Kempf MC, Graham L, et al. HIV and Hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health 2010;10:777
- 2. Solomon L, Montague BT, Beckwith CG, et al. Survey finds that many prisons and jails have room to improve HIV testing and coordination of post release treatment. Health affairs. 2014;33:434-442
- 3. Varan AK, Mercer DW, Stein MS, et al. Hepatitis C Seroprevalence Among Prison Inmates Since 2001: Still High but Declining. Public Health Rep. 2014 Mar-Apr;129: 187-95
- 4. Beckman AL, Bilinski A, Boyko R, et al. New Hepatitis C Drugs Are Very Costly and Unavailable to Many State Prisoners. Health Affairs
- 5. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States---an analysis of cost-effectiveness. N Engl J Med 2005;352:586--95

ACKNOWLEDGEMENTS: We would like to acknowledge GILEAD Sciences, Inc. FOCUS program for funding of the opt-out HIV/HCV testing program